Search Results

You are looking at 1 - 1 of 1 items for

  • Author: EM Berghout x
  • Refine by access: All content x
Clear All Modify Search
JW van Neck
Search for other papers by JW van Neck in
Google Scholar
PubMed
Close
,
EM Berghout
Search for other papers by EM Berghout in
Google Scholar
PubMed
Close
,
L Vinter-Jensen
Search for other papers by L Vinter-Jensen in
Google Scholar
PubMed
Close
,
CA Groffen
Search for other papers by CA Groffen in
Google Scholar
PubMed
Close
,
V Cingel
Search for other papers by V Cingel in
Google Scholar
PubMed
Close
,
NF Dits
Search for other papers by NF Dits in
Google Scholar
PubMed
Close
,
SL Drop
Search for other papers by SL Drop in
Google Scholar
PubMed
Close
, and
A Flyvbjerg
Search for other papers by A Flyvbjerg in
Google Scholar
PubMed
Close

Systemic administration of epidermal growth factor (EGF) in neonatal rats results in reduced body weight gain and decreased circulating levels of IGF-I, suggesting its involvement in EGF-induced growth retardation. We investigated the effect of EGF and/or IGF-I administration for 7 days on circulating IGF-I and IGFBP levels and hepatic and renal IGF-system mRNA expression profiles in adult female rats. EGF administration (30 microg/rat/day) did not influence body weight, liver or kidney weight. In contrast, IGF-I (400 microg/rat/day) and EGF/IGF-I administration increased both body weight and kidney weight. Also, serum IGF-I and the 30 kDa IGFBPs (IGFBP-1 and -2) were significantly increased in these groups. Serum IGFBP-3 levels increased in the IGF-I group along with increased hepatic IGFBP-1 and -3 mRNA levels. In contrast, in the EGF administration group serum IGFBP-3 levels were significantly decreased; however, the mRNA levels remained unchanged. In the EGF/IGF-I administration group, serum IGF-I and IGFBP-3 levels were significantly lowered when compared with the IGF-I administration group. This was in contrast to the effect on kidney weight increase that was identical for the IGF-I and EGF/IGF-I groups. The decrease in serum IGFBP-3 was not reflected at the hepatic IGFBP-3 mRNA level. IGFBP-3 expression might be regulated at a post-transcriptional level although EGF induced IGFBP-3 proteolysis could not be demonstrated in vitro. We conclude that EGF administration reduced serum IGFBP-3 whereas IGF-I administration increased the level of IGFBP-3 and IGF-I and resulted in an increased body and kidney weight in adult female rats.

Free access